Ignite Creation Date:
2024-05-06 @ 2:13 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01998126
Status:
COMPLETED
Last Update Posted:
2018-04-02
First Post:
2013-07-11
Brief Title:
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
University of Utah
Organization:
University of Utah
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-12-02
Start Date Type:
ACTUAL
Primary Completion Date:
2017-05-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-03-29
Completion Date Type:
ACTUAL
First Submit Date:
2013-07-11
First Submit QC Date:
November 22 2013
Study First Post Date:
2013-11-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-03-30
Last Update Post Date:
2018-04-02
Last Update Post Date Type:
ACTUAL